Krystal Biotech price target raised to $153 from $148 at Chardan

Chardan raised the firm’s price target on Krystal Biotech to $153 from $148 and keeps a Buy rating on the shares. The company reported Q2 results, provided an update on the Vyjuvek launch, and highlighted regulatory and clinical priorities across the pipeline, the analyst tells investors in a research note. The firm views Vyjuvek demand as “robust.”